Articles

GM to idle Fort Wayne plant for nine weeks

General Motors Co., preparing to introduce new pickups in 2013, has scheduled 21 weeks without production at three U.S. full-size truck plants next year to update the factories for building the new models.

Read More

Honda reworking Civic in plan to boost sales

Honda Motor Co. is sprucing up its Indiana-made Civic sedan, which received poor ratings, after less than a year on the market as part of a plan to boost U.S. sales by 24 percent in 2012 for its namesake brand.

Read More

Republic Air unit among best in airline hassle rankings

Coach passengers on American Airlines and US Airways Group Inc. jets have the greatest risk of hassles, according to new rankings. Southwest Airlines Co. and Frontier Airlines, a unit of Indianapolis-based Republic Airways, posted the highest scores.

Read More

Thanksgiving weekend retail sales jump to record $52.4B

U.S. retail sales during Thanksgiving weekend climbed 16 percent to a record, as shoppers flocked to stores earlier and spent more, according to the National Retail Federation. Sales totaled $52.4 billion, and the average shopper spent $398.62 over the holiday weekend, up from $365.34 a year earlier.

Read More

UnitedHealth to acquire Medicare insurer XLHealth

UnitedHealth Group Inc. said it will acquire XLHealth Corp., a provider of managed care for chronically ill Medicare members. Indianapolis-based WellPoint Inc. had been considering a possible acquisition of the company.

Read More

Angie’s List IPO raises $114 million

Angie’s List Inc., the Indianapolis-based consumer-review service with more than 1 million paying members, raised about $114 million in its initial public offering Wednesday after pricing the shares at the top end of the proposed range.

Read More

Potential Lilly drug doubles good cholesterol

Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.

Read More

Potential Effient rival shows promise in study

A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.

Read More